Verrica Pharmaceuticals Inc. Share Price & Technical Analysis
VRCA · $6.06 (+2.71%)
Healthcare / Biotechnology
$6.06
+2.71%
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the tre…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-5% return in May, 5% avg return in past 3 year May month.
-27% return in 2026, 26% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -18% | -26% | 0% | 21% | -5% | – | – | – | – | – | – | – | -27% |
| 25 | -7% | 3% | -34% | 5% | 2% | 8% | 4% | 0% | -23% | -16% | 146% | 4% | 90% |
| 24 | -22% | -7% | 9% | 18% | 21% | -16% | -8% | -65% | -38% | -5% | -10% | -47% | -170% |
| 23 | 63% | 70% | -18% | -7% | -8% | 1% | 1% | -21% | -15% | -6% | -1% | 98% | 158% |
| 22 | -11% | 1% | -4% | -19% | -70% | -1% | 58% | 26% | -25% | -16% | 29% | -11% | -45% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$118.71M
P/E ratio
—
52W high
$9.82
52W low
$3.28
Volume
71,896
Beta
1.55
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Verrica Pharmaceuticals Inc. share price today?
- Verrica Pharmaceuticals Inc. (VRCA) last traded around $6.06 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does VRCA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for VRCA. Download the app for real-time alerts.
- How can I analyze Verrica Pharmaceuticals Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.